Efficient reprogramming protocols for regenerative medicine.

In order to faciliate the translation of our academic work Mogrify Limited is utilising it in it's own R+D and via commerical partnerships. Cell Mogrify is open to partnering with life science companies to license, acquire, or for joint development of novel protocols for cell reprogramming. For further information please visit the website or contact them directly.